Rucaparib Uses, Dosage, Side Effects and Interactions
Rubraca
Rubraca was the first rucaparib product the FDA approved, in December 2016. No generic is listed as tablets.
Rucaparib is a PARP inhibitor, a targeted cancer medicine used for BRCA-mutated ovarian, fallopian tube and primary peritoneal cancer, and for BRCA-mutated metastatic castration-resistant prostate cancer.
Quick links
Ask Anything About RucaparibType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Rucaparib in Short
- Drug class Poly(ADP-Ribose) Polymerase Inhibitor How the FDA classifies it
What it treatsRucaparib (sold as Rubraca tablets) treats certain cancers that carry a harmful BRCA gene mutation. Your doctor decides if it fits based on your cancer and genetic testing. Rubraca is used in two ways: as maintenance treatment for recurrent ovarian, fallopian tube or primary peritoneal cancer after a response to…
- How you get it Prescription only
- Comes asTablet (by mouth)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs105 interact 2 major, 78 moderate and 25 minor
- Generic launchsometime in 2031 Our estimate for the first generic of Rubraca
The Pharmacist’s Take
Rucaparib (Rubraca) is a targeted tablet, prescribed by cancer specialists, for BRCA-mutated ovarian, fallopian tube and primary peritoneal cancer and for BRCA-mutated prostate cancer that has spread despite hormone treatment. It blocks PARP enzymes that repair damaged DNA, so damage builds up and cancer cells die. It has been available since about 2016, with no generic yet. Nausea, tiredness and a changed sense of taste are the common complaints, usually manageable with a dose reduction. The serious risk is a blood cancer (MDS or AML) that has been fatal in some people, so blood counts are checked before you start and every month.
Key Takeaways From the HelloPharmacist Team
- Take it by mouth twice a day, with or without food, usually for as long as it keeps the cancer in check.
- Call your cancer team about ongoing tiredness, easy bruising or bleeding, or frequent infections, which can signal a falling blood count.
- Use effective birth control during treatment and for 6 months after (3 months for men with partners who could become pregnant).
- Rucaparib raises levels of many drugs, including warfarin and caffeine, so share your full medicine list; warfarin users may need closer INR (clotting) checks.
Patient Information Guide for Rucaparib
What It’s Used For
Rucaparib treats certain BRCA-mutated cancers.
- Rubraca tablets: maintenance treatment of BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in adults who responded to platinum-based chemotherapy.
- Rubraca tablets: treatment of BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in adults previously treated with androgen receptor-directed therapy.
How It Works
Rucaparib blocks PARP enzymes (PARP-1, PARP-2 and PARP-3) that help cells repair their DNA. Blocking them causes DNA damage to build up and can lead to cancer cell death.
In lab studies, cancer cells with BRCA1/2 or other DNA repair gene deficiencies were more sensitive to rucaparib.
Drug Class
Drug Class
- Poly(ADP-Ribose) Polymerase Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Poly(ADP-Ribose) Polymerase Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Poly(ADP-Ribose) Polymerase Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Rucaparib in the FDA’s index.
From our Patient Information GuideRucaparib blocks PARP enzymes (PARP-1, PARP-2 and PARP-3) that help cells repair their DNA. Blocking them causes DNA damage to build up and can lead to cancer cell death. Read How Rucaparib Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Rucaparib in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Poly (ADP-ribose) polymerase (PARP) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Rubraca is taken by mouth as tablets twice a day, with or without food. Treatment continues until the disease progresses or side effects become unacceptable.
- Your doctor may interrupt treatment or lower the dose to manage side effects.
- For prostate cancer, you should also take a GnRH analog (a hormone-lowering medicine) unless you have had surgical removal of the testicles.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Ovarian cancer maintenance treatment and BRCA-mutated prostate cancer that has spread
For adults · Starting dose
Usual dose 600 mg twice a day
- 600 mg (two 300 mg tablets) taken orally twice daily with or without food, for a total daily dose of 1,200 mg
- Continue until disease progression or unacceptable toxicity
Good to know
Patients receiving Rubraca for mCRPC should also receive a GnRH analog concurrently or have had bilateral orchiectomy
Special Situations
If side effects need a lower dose
Your doctor decides whether to lower your dose for side effects. Never change your dose on your own.
-
First dose reduction
500 mg twice daily (two 250 mg tablets)
-
Second dose reduction
400 mg twice daily (two 200 mg tablets)
-
Third dose reduction
300 mg twice daily (one 300 mg tablet)
Side Effects
Common side effects include:
Common side effects
- Nausea and vomiting
- Tiredness or weakness
- Low red blood cells (anemia)
- Raised liver tests (ALT/AST)
- Diarrhea or constipation
- Decreased appetite
- Low platelets
- Changed sense of taste
- Anemia, low platelets, low white blood cells
- Shortness of breath and dizziness
- Sun sensitivity (photosensitivity)
- Muscle and bone pain, edema and rash in prostate cancer patients
When to get medical help
- Call your doctor about ongoing tiredness, easy bruising or bleeding, or frequent infections, which can signal low blood counts or a serious blood problem (MDS/AML).
- Get medical help for signs of a heart attack or a blood clot in the lung (pulmonary embolism), which were reported in prostate cancer patients.
- Tell your doctor right away if you become pregnant or think you might be.
- Call your doctor about severe or persistent vomiting or diarrhea, or a urinary tract infection.
Contact your doctor about signs of low blood counts, serious infection, or heart or lung problems such as chest pain or sudden shortness of breath.
Warnings and Precautions
The biggest risk is MDS/AML, serious blood cancers that can be fatal. In studies, MDS/AML occurred in 1.6% of 2141 treated patients. Blood counts are checked before treatment and monthly afterward.
Rucaparib can also cause fetal harm, so contraception and pregnancy testing are important.
Interactions
Rucaparib can raise levels of other medicines.
- CYP1A2, CYP3A, CYP2C9 and CYP2C19 substrates: levels can rise, which may increase their side effects; doses may need lowering.
- Warfarin: more frequent INR monitoring may be needed.
Interactions Listed in the FDA-Approved Label
From the Rucaparib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
CYP1A2, CYP3A, CYP2C9, or CYP2C19 substratesWhat happensRubraca can increase the systemic exposure of these substrates, which may increase the frequency or severity of their adverse reactions.What to doIf use together is unavoidable where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with its approved prescribing information.
-
What happensRubraca can increase warfarin exposure, as a CYP2C9 substrate.What to doIf concomitant administration cannot be avoided, consider increasing the frequency of INR monitoring.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 Effect of Rubraca on Other Drugs Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates, which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information. If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.
7.1 Effect of Rubraca on Other Drugs Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates, which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information. If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.
Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates, which may increase the frequency or severity of adverse reactions of these substrates.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Pregnancy: can cause fetal harm; a pregnancy test is recommended first.
- Breastfeeding: not advised during treatment and for 2 weeks after the last dose.
- Children: safety and effectiveness not established.
- Older adults: no major safety differences were seen.
- Kidney or liver impairment: no dose change for mild to moderate impairment; not studied in severe impairment or dialysis.
Half-Life and How Your Body Processes It
Rucaparib is absorbed after swallowing, with peak levels about 2 hours later. A high-fat meal raised absorption modestly. It is mainly broken down by the CYP2D6 enzyme and, to a lesser extent, CYP1A2 and CYP3A4. Its average half-life is about 26 hours. Moderate liver impairment raised exposure by 45%.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Rucaparib
From the licensed clinical database we use, rolled up per supplement, most serious first.105 supplements and herbal products have documented interactions with Rucaparib in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 2Major
- 78Moderate
- 25Minor
- ACTIVATED CHARCOALMajor
- ST. JOHN'S WORTMajor
- 1,3-DMAAModerate
- ACACIA RIGIDULAModerate
- ACTIVE HEXOSE CORRELATED COMPOUND (AHCC)Moderate
- AYAHUASCAModerate
- BERBERINEModerate
- BETA-METHYLPHENETHYLAMINE (BMPEA)Moderate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Rucaparib: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Rucaparib — the kind of thing our pharmacy team would talk through with you at the counter.
What is rucaparib used for?
Do I take rucaparib with food?
What side effects should I expect?
Why do I need regular blood tests on rucaparib?
Can I take rucaparib if I'm pregnant or breastfeeding?
Does rucaparib interact with other medicines?
Is rucaparib available over the counter?
When was rucaparib first available?
What is the brand name of rucaparib?
What is the generic name of Rubraca?
What drug class is rucaparib?
What strengths does rucaparib come in?
Is there a rucaparib shortage?
Where can I read the rucaparib prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Rucaparib
Skip the scrolling. Ask in your own words and get an answer from Rucaparib’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Rucaparib’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Rucaparib on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Rucaparib Forms and Strengths (How It Comes)
Rucaparib comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Rucaparib inactive ingredients by manufacturer.
Tablet
How this form is used
- Rubraca is used as maintenance treatment of BRCA-mutated recurrent ovarian, fallopian tube or primary peritoneal cancer after a response to platinum-based chemotherapy.
- Rubraca is used to treat BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor-directed therapy.
- Rubraca tablets are taken by mouth twice daily, with or without food.
- Rubraca treatment generally continues until the disease progresses or side effects become unacceptable.
- Rubraca may be taken with a GnRH analog in prostate cancer, unless you have had an orchiectomy (surgical removal of the testicles).
Rucaparib on the U.S. Market: Products, Makers and Brands
How Rucaparib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 3 Rucaparib product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2016. The one brand name in the directory today is Rubraca; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished tablet, film coated (3) · Powder (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Compare Rucaparib Products
A representative set of FDA-listed product records for Rucaparib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 200 mg | Oral | pharmaand GmbH | NDA | View NDC → |
| 250 mg | Oral | pharmaand GmbH | NDA | View NDC → |
| 300 mg | Oral | pharmaand GmbH | NDA | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Rucaparib NDCs →
Rucaparib Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Rucaparib — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Rucaparib in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Rucaparib FDA Approval History
How Rucaparib went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Rucaparib Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Rucaparib recalls since July 2021.
✅No Rucaparib recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Rucaparib in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 3
- Forms in current FDA listings
- 1 of 1
RxCUI 1862579 RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Rucaparib Supply and Shortage Status
Whether Rucaparib is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Rucaparib Brand Names
Rucaparib has one brand name on record: Rubraca. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Rucaparib: Manufacturers and Labelers
One company lists Rucaparib products with the FDA. By number of product records, the largest are pharmaand GmbH. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Rucaparib Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. pharmaand GmbH is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →